SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-018539
Filing Date
2023-05-22
Accepted
2023-05-22 16:10:43
Documents
36
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 277595
2 ex31-1.htm EX-31.1 17722
3 ex32-1.htm EX-32.1 6423
  Complete submission text file 0001493152-23-018539.txt   1675012

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE glsi-20230331.xsd EX-101.SCH 13118
5 XBRL CALCULATION FILE glsi-20230331_cal.xml EX-101.CAL 20135
6 XBRL DEFINITION FILE glsi-20230331_def.xml EX-101.DEF 52924
7 XBRL LABEL FILE glsi-20230331_lab.xml EX-101.LAB 132885
8 XBRL PRESENTATION FILE glsi-20230331_pre.xml EX-101.PRE 105505
30 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 128154
Mailing Address 3992 BLUEBONNET DR, BUILDING 14 STAFFORD TX 77477
Business Address 3992 BLUEBONNET DR, BUILDING 14 STAFFORD TX 77477 203-434-3290
Greenwich LifeSciences, Inc. (Filer) CIK: 0001799788 (see all company filings)

IRS No.: 205473709 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39555 | Film No.: 23944518
SIC: 2834 Pharmaceutical Preparations